The receptor tyrosine kinase Mer promotes multiple myeloma progression and osteolytic bone disease

被引：0
|
作者：
Engelmann, J. [1 ,2 ]
Ben Batalla, I. [1 ,2 ]
Taipaleenmaeki, H. [3 ]
Riecken, K. [4 ]
Gensch, V. [1 ,2 ]
Paesler, S. [1 ,2 ]
Berenbrok, N. [1 ,2 ]
Vargas, M. E. [1 ,2 ]
Waizenegger, J. [2 ]
Fehse, B. [4 ]
Pantel, K. [2 ]
Darwish, I. [5 ]
Bhamidipati, S. [5 ]
Masuda, E. [5 ]
Bokemeyer, C. [1 ]
Hesse, E. [3 ]
Loges, S. [1 ,2 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Med Klin & Poliklin 2, Abt Pneumol, Onkol,Hamatol,Knochenmarktransplantat, Hamburg, Germany
[2] Univ Klinikum Hamburg Eppendorf, Inst Tumorbiol, Hamburg, Germany
[3] Univ Klinikum Hamburg Eppendorf, Expt Unfallchirurg, Heisenberg Arbeitsgrp, Hamburg, Germany
[4] Univ Klinikum Hamburg Eppendorf, Interdisziplinare Klin & Poliklin Stammzelltransp, Hamburg, Germany
[5] Rigel Pharmaceut Inc, San Francisco, CA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2019年 / 42卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P708
引用
收藏
页码：190 / 190
页数：1
相关论文
共 50 条
  • [41] Activity of tyrosine kinase inhibitors in multiple myeloma
    Munker, Reinhold
    Cordova, Cory
    Polk, Paula
    Wendling, Charles V.
    Sun, Amanda W.
    Cardelli, James A.
    BLOOD, 2007, 110 (11) : 274B - 274B
  • [42] Cell Adhesion Molecule CD166 Drives Malignant Progression and Osteolytic Disease in Multiple Myeloma
    Xu, Linlin
    Mohammad, Khalid S.
    Wu, Hao
    Crean, Colin
    Poteat, Bradley
    Cheng, Yinghua
    Cardoso, Angelo A.
    Machal, Christophe
    Hanenberg, Helmut
    Abonour, Rafat
    Kacena, Melissa A.
    Chirgwin, John
    Suvannasankha, Attaya
    Srour, Edward F.
    CANCER RESEARCH, 2016, 76 (23) : 6901 - 6910
  • [43] AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
    Yan, Siyang
    Vandewalle, Niels
    De Beule, Nathan
    Faict, Sylvia
    Maes, Ken
    De Bruyne, Elke
    Menu, Eline
    Vanderkerken, Karin
    De Veirman, Kim
    CANCERS, 2019, 11 (11)
  • [44] A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
    S. T. Lwin
    J. A. Fowler
    M. T. Drake
    J. R. Edwards
    C. C. Lynch
    C. M. Edwards
    Molecular Cancer, 16
  • [45] A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
    Lwin, S. T.
    Fowler, J. A.
    Drake, M. T.
    Edwards, J. R.
    Lynch, C. C.
    Edwards, C. M.
    MOLECULAR CANCER, 2017, 16 : 49
  • [46] Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
    Shin, Dongyeop
    Kim, Myung-Jin
    Chun, Soyeon
    Kim, Dongchan
    Lee, Chansu
    Ahn, Kwang-Sung
    Jung, Eunyoung
    Kim, Dayeon
    Lee, Byung-Chul
    Hwang, Daehee
    Kim, Yonghwan
    Yoon, Sung -Soo
    HAEMATOLOGICA, 2024, 109 (07) : 2207 - 2218
  • [47] Regenerative stem cell therapy for multiple myeloma osteolytic bone damage
    Higgs, Jerome T.
    Jarboe, John
    Ponnazhagan, Selvarangan
    CANCER RESEARCH, 2011, 71
  • [48] MECHANISMS OF OSTEOLYTIC BONE DESTRUCTION IN MULTIPLE-MYELOMA IN-VIVO
    ALSINA, M
    DEVLIN, R
    ROODMAN, GD
    JOURNAL OF BONE AND MINERAL RESEARCH, 1995, 10 : S503 - S503
  • [49] Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
    Shin, Dongyeop
    Kim, Myung-Jin
    Chun, Soyeon
    Kim, Dongchan
    Lee, Chansu
    Ahn, Kwang-Sung
    Jung, Eunyoung
    Kim, Dayeon
    Lee, Byung-Chul
    Hwang, Daehee
    Kim, Yonghwan
    Yoon, Sung -Soo
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2207 - 2218
  • [50] The Receptor Tyrosine Kinase AXL in Cancer Progression
    Rankin, Erinn B.
    Giaccia, Amato J.
    CANCERS, 2016, 8 (11):
12345